Hypothesis

Brain‑derived exosomes carrying miR‑296‑5p set the intestinal barrier tone, and their age‑related decline initiates a gut‑first cascade that drives neurodegeneration.

Mechanistic Rationale

• Neuronal activity, especially in the hypothalamus, triggers release of exosomes enriched in miR‑296‑5p into the circulation (2).
• These exosomes cross the gut vasculature and are taken up by enteric endothelial cells, where miR‑296‑5p suppresses TXNIP‑driven oxidative stress, preserving tight‑junction proteins (claudin‑1, occludin) and limiting barrier permeability.
• With advancing age, neuronal exosome output falls (mirroring the drop in circulating miR‑296‑5p), weakening this suppressive signal. The resulting rise in endothelial TXNIP increases ROS, loosens tight junctions, and allows bacterial products to enter the lamina propria.
• Barrier breach fuels dysbiosis, shifting the microbiota toward strains that release exosomes carrying pro‑ferroptotic cargos (3). Those gut‑derived exosomes then travel back to the brain, amplifying hippocampal ferroptosis and neuroinflammation.
• Thus, the primary driver of the gut‑brain axis in aging is a top‑down loss of neuronal exosomal signaling, not a bottom‑up microbial push.

Testable Predictions

1. Old mice administered purified brain‑derived exosomes enriched for miR‑296‑5p will show restored intestinal barrier integrity (lower FITC‑dextran flux) compared with vehicle‑treated controls.
2. Barrier rescue will correlate with a shift in fecal microbiota composition toward higher SCFA‑producing taxa and reduced abundance of ferroptosis‑inducing bacterial strains.
3. Concurrently, hippocampal tissue will exhibit decreased ATG5/COX2 and increased GPX4/FTH1, indicating suppressed ferroptosis, and spatial memory performance will improve in the Morris water maze.
4. Genetic knockout of neuronal exosome release (e.g., conditional Rab27a deletion in forebrain neurons) will accelerate gut permeability decline and shorten lifespan, even when microbiota is kept germ‑free.

Experimental Design

• Exosome isolation: Immunopurify exosomes from young mouse cerebral cortex using anti‑CD63 beads; quantify miR‑296‑5p by qPCR.
• Treatment groups (n=12 per group): aged (20‑month) C57BL/6 mice receive i.v. injections of (a) miR‑296‑5p‑enriched brain exosomes, (b) exosomes from young gut microbiota (control for gut‑derived vesicles), (c) PBS vehicle. Dosing twice weekly for 8 weeks.
• Readouts:
  • Gut permeability: oral FITC‑dextran assay, serum fluorescence.
  • Barrier proteins: Western blot of colonic claudin‑1, occludin.
  • Microbiota: 16S rRNA sequencing; calculate SCFA‑producer ratio.
  • Gut‑derived exosomes: isolate from feces, assay miR‑296‑5p and ferroptosis‑related cargo.
  • Brain outcomes: hippocampal GPX4, FTH1, ATG5, COX2 levels; ferroptosis iron assay; neurodegeneration markers (NeuN loss).
  • Behavior: Morris water maze acquisition and probe trial.
  • Survival: monitor lifespan until natural death.

Potential Outcomes and Falsification

• Support: Exosome treatment restores barrier, shifts microbiota, reduces hippocampal ferroptosis markers, improves cognition, and extends median lifespan (>10% increase vs. vehicle).
• Refute: No change in gut permeability or microbiota despite confirmed delivery of neuronal exosomes; or barrier rescue fails to improve brain outcomes, indicating gut‑derived signals dominate.
• Alternative: If Rab27a neuronal knockout does not exacerbate gut permeability in germ‑free mice, the hypothesis that neuronal exosomes act directly on the gut is weakened, suggesting indirect pathways (e.g., via vagal efferents).

This framework flips the prevailing bottom‑up bias, offering a concrete, falsifiable route to test whether boosting brain‑to‑gut exosomal signaling can re‑set the gut‑brain axis and delay aging.